MX2021003794A - Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso. - Google Patents

Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso.

Info

Publication number
MX2021003794A
MX2021003794A MX2021003794A MX2021003794A MX2021003794A MX 2021003794 A MX2021003794 A MX 2021003794A MX 2021003794 A MX2021003794 A MX 2021003794A MX 2021003794 A MX2021003794 A MX 2021003794A MX 2021003794 A MX2021003794 A MX 2021003794A
Authority
MX
Mexico
Prior art keywords
methods
thieno
pyridine derivatives
udp glycosyltransferase
glycosyltransferase inhibitors
Prior art date
Application number
MX2021003794A
Other languages
English (en)
Inventor
Mark Munson
Elina Makino
Sachin Maniar
Bradford Hirth
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
John JIANG
Yong- Mi CHOI
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2021003794A publication Critical patent/MX2021003794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se divulga un compuesto de Fórmula (I), como se describe en el presente documento, y sus sales farmacéuticamente aceptables. También se describen en el presente documento composiciones y el uso de tales composiciones en métodos para tratar una variedad de enfermedades y afecciones, en particular la enfermedad de Krabbe (KD) y la leucodistrofia metacromática (MLD).
MX2021003794A 2018-10-01 2019-10-01 Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso. MX2021003794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
MX2021003794A true MX2021003794A (es) 2021-09-08

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003794A MX2021003794A (es) 2018-10-01 2019-10-01 Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso.

Country Status (15)

Country Link
US (1) US11098056B2 (es)
EP (1) EP3861000A1 (es)
JP (1) JP2022508523A (es)
KR (1) KR20210087033A (es)
CN (1) CN113423711B (es)
AU (1) AU2019355870B2 (es)
BR (1) BR112021005914A2 (es)
CA (1) CA3114722A1 (es)
CO (1) CO2021005738A2 (es)
IL (1) IL281811A (es)
MA (1) MA53043B2 (es)
MX (1) MX2021003794A (es)
SG (1) SG11202102987VA (es)
TW (1) TWI821426B (es)
WO (1) WO2020072504A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507222A (ja) * 2021-02-19 2024-02-16 カルビスタ・ファーマシューティカルズ・リミテッド 第ＸＩＩａ因子阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
AU6621600A (en) * 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
CA2703600C (en) * 2007-11-15 2017-04-25 Ym Biosciences Australia Pty Ltd Fused thieno or pyrrolo pyrimidine heterocyclic compounds and use thereof as jak1, jak2, and/or jak3 inhibitors
SG173584A1 (en) * 2009-02-06 2011-09-29 Elan Pharm Inc Inhibitors of jun n-terminal kinase
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
ES2928714T3 (es) * 2015-01-16 2022-11-22 Massachusetts Gen Hospital Compuestos para mejorar el empalme del ARNm
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3468954A1 (en) 2016-06-10 2019-04-17 BioMarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
US20190322676A1 (en) 2016-12-20 2019-10-24 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MX2019013148A (es) * 2017-05-04 2019-12-18 Glenmark Pharmaceuticals Sa Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Also Published As

Publication number Publication date
US11098056B2 (en) 2021-08-24
BR112021005914A2 (pt) 2021-06-29
TW202035419A (zh) 2020-10-01
US20200102324A1 (en) 2020-04-02
AU2019355870B2 (en) 2023-11-16
MA53043B2 (fr) 2024-05-31
JP2022508523A (ja) 2022-01-19
KR20210087033A (ko) 2021-07-09
CN113423711A (zh) 2021-09-21
CO2021005738A2 (es) 2021-05-10
SG11202102987VA (en) 2021-04-29
IL281811A (en) 2021-05-31
CA3114722A1 (en) 2020-04-09
WO2020072504A1 (en) 2020-04-09
EP3861000A1 (en) 2021-08-11
CN113423711B (zh) 2024-03-15
MA53043A1 (fr) 2022-08-31
TWI821426B (zh) 2023-11-11
AU2019355870A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2023001876A (es) Derivados de rapamicina.
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
SG10201903579SA (en) Indole carboxamides compounds useful as kinase inhibitors
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
PH12020552283A1 (en) Pyrrolo[1,2-b] pyridazine derivatives
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021007247A (es) Derivados de rapamicina.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
SG11201907945YA (en) Azetidine derivative
MX2021003794A (es) Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso.
PH12021550557A1 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
ZA202303913B (en) Pyrimidine carboxamide compound and application thereof
MX2022004713A (es) Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.